NCT05939362

New Imaging Biomarkers Predictive of MA Progression

Identifying Imaging Biomarkers Predictive of Disability Progression in Alzheimer's Disease: Pilot Study

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Poitiers University Hospital · Academic / Other
• Sex: All
• Age: 60 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The pathophysiology of AD is complex. In addition to amyloid plaques and neurofibrillary degeneration, there is a metabolic alteration of the energy pathways, oxidative phosphorylation and glycolysis, which are involved in brain function. Several authors have shown a series of early metabolic dysregulations via an increase in phosphorylation at the origin of neuronal death. Ultra-high field imaging (7T MRI) may allow, with its better spatial resolution and advanced imaging techniques, to shed light on the mechanisms of progression of Alzheimer's disease. A Magnetic Resonance Spectroscopy (MRS) examination can be coupled to brain MRI without additional risk for the patient. Multinuclear 1H-31P metabolic imaging is a promising tool that can provide information on the metabolic evolutionary profile of AD. Thus, we propose a longitudinal study in patients with early-stage AD on 7T MRI-MRS.

Conditions

• Alzheimer Disease
• Magnetic Resonance Spectroscopy
• Ultra High Field 7T
• Progression of Disease
• MR Biomarkers

Interventions

Type	Name	Description
OTHER	MRI follow-up	MRI follow-up for patient with early onset Alzheimer's disease

Timeline

• Start date: 2023-10-02
• Primary completion: 2027-10-02
• Completion: 2028-01-15
• First posted: 2023-07-11
• Last updated: 2024-12-10

Locations

1 site across 1 country: France